The first RSV vaccine for older adults is now available in some US pharmacies. GSK’s Arexvy (palivizumab) was approved by the FDA in May 2023 and is indicated for the prevention of lower respiratory tract disease (LRTD) caused by RSV in adults aged 60 and older.
GSK RSV Vaccine Now Available in Some US Pharmacies
RSV is a common respiratory virus that can cause mild, cold-like symptoms in healthy adults. However, it can be more serious in older adults, infants, and children with underlying health conditions. RSV can lead to pneumonia, bronchiolitis, and even death.
Arexvy is a single-dose vaccine that is administered by injection. It is not a live vaccine, so it cannot cause RSV infection. The vaccine is 83% effective in preventing LRTD in adults aged 60 and older.
Arexvy is not yet available in all US pharmacies. However, it is expected to become more widely available in the coming months. The vaccine is not currently covered by insurance, but this may change in the future.
If you are an older adult who is at risk for RSV infection, talk to your doctor about whether Arexvy is right for you. The vaccine can help protect you from serious RSV illness and keep you healthy during the winter months.
Here are some additional things to know about Arexvy:
- It is a preventive vaccine, not a treatment for RSV infection.
- It is not recommended for pregnant women or women who are breastfeeding.
- It is safe for most people, but there are some rare side effects that can occur.
If you have any questions about Arexvy, talk to your doctor.